Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.57
-1.42 (-7.48%)
At close: Nov 5, 2026, 4:00 PM EST
17.18
-0.39 (-2.22%)
After-hours: Nov 5, 2026, 7:55 PM EST
Sarepta Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,956 | 2,198 | 1,902 | 1,243 | 933.01 | 701.89 | |
Revenue Growth | -18.95% | 15.58% | 52.97% | 33.26% | 32.93% | 29.95% |
Cost of Revenue | 2,367 | 2,362 | 1,124 | 1,028 | 1,017 | 862.13 |
Gross Profit | -411.1 | -163.43 | 778.36 | 215.61 | -84.07 | -160.24 |
Selling, General & Admin | 463.46 | 491.72 | 557.87 | 481.87 | 451.42 | 282.66 |
Research & Development | -868.96 | - | - | - | - | - |
Amortization of Goodwill & Intangibles | 2.8 | 2.62 | 2.41 | 1.56 | 0.71 | 0.71 |
Operating Expenses | -402.7 | 494.34 | 560.28 | 483.43 | 452.14 | 283.37 |
Operating Income | -8.4 | -657.77 | 218.08 | -267.82 | -536.2 | -443.61 |
Interest Expense | -38.14 | -38.14 | -18.39 | -22.01 | -53.25 | -63.53 |
Interest & Investment Income | 30.76 | 30.76 | 30.64 | 36.26 | 16.49 | 0.35 |
Other Non Operating Income (Expenses) | -38.85 | -1.94 | -0.06 | -0.91 | -6.92 | -0.94 |
EBT Excluding Unusual Items | -54.63 | -667.09 | 230.27 | -254.49 | -579.88 | -507.72 |
Merger & Restructuring Charges | -1.5 | -42.01 | - | - | - | - |
Gain (Loss) on Sale of Investments | -9.99 | -9.99 | 38.35 | 20.92 | 8.66 | -4.33 |
Gain (Loss) on Sale of Assets | - | - | - | 102 | - | 102 |
Other Unusual Items | 13.1 | 16.86 | -7.84 | -388.53 | -118.74 | -8.9 |
Pretax Income | -92.02 | -702.23 | 260.77 | -520.1 | -689.96 | -418.95 |
Income Tax Expense | 22.6 | 11.19 | 25.54 | 15.88 | 13.53 | -0.17 |
Net Income | -114.62 | -713.41 | 235.24 | -535.98 | -703.49 | -418.78 |
Net Income to Common | -114.62 | -713.41 | 235.24 | -535.98 | -703.49 | -418.78 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 105 | 100 | 95 | 92 | 88 | 81 |
Shares Outstanding (Diluted) | 105 | 100 | 108 | 92 | 88 | 81 |
Shares Change | 7.47% | -7.19% | 16.75% | 5.53% | 7.75% | 4.24% |
EPS (Basic) | -1.09 | -7.13 | 2.47 | -5.80 | -8.03 | -5.15 |
EPS (Diluted) | -1.09 | -7.13 | 2.34 | -5.80 | -8.03 | -5.15 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 176.4 | -307.45 | -342.74 | -577.1 | -356.17 | -481.66 |
Free Cash Flow Per Share | 1.68 | -3.07 | -3.18 | -6.25 | -4.07 | -5.93 |
Gross Margin | -21.01% | -7.43% | 40.92% | 17.34% | -9.01% | -22.83% |
Operating Margin | -0.43% | -29.92% | 11.47% | -21.54% | -57.47% | -63.20% |
Profit Margin | -5.86% | -32.45% | 12.37% | -43.11% | -75.40% | -59.66% |
Free Cash Flow Margin | 9.02% | -13.99% | -18.02% | -46.41% | -38.17% | -68.62% |
EBITDA | 23.76 | -613.25 | 255.81 | -223.43 | -494.34 | -405.59 |
EBITDA Margin | 1.21% | -27.90% | 13.45% | -17.97% | -52.98% | -57.79% |
D&A For EBITDA | 32.16 | 44.52 | 37.72 | 44.4 | 41.86 | 38.02 |
EBIT | -8.4 | -657.77 | 218.08 | -267.82 | -536.2 | -443.61 |
EBIT Margin | -0.43% | -29.92% | 11.47% | -21.54% | -57.47% | -63.20% |
Effective Tax Rate | - | - | 9.79% | - | - | - |
Revenue as Reported | 1,956 | 2,198 | 1,902 | 1,243 | 933.01 | 701.89 |
Advertising Expenses | - | 29.5 | 32 | 28.6 | 14.6 | 7.7 |